ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 15 for:    GSK 1278863 | Phase 2, 3

Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02075463
Recruitment Status : Terminated
First Posted : March 3, 2014
Results First Posted : June 21, 2017
Last Update Posted : June 21, 2017
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
The study will evaluate the ability of GSK1278863 to increase the hemoglobin (Hgb) concentration, or maintain it within the target range, and the safety and efficacy of GSK1278863 over 16 weeks of treatment, in hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are chronically hyporesponsive to rhEPO. The data generated will inform dose requirements for any chronic rhEPO hyporesponsive hemodialysis-dependent subjects included in future clinical trials. The study consists of a 4-week rhEPO run-in period, a 16-week GSK1278863 treatment period and a 4-week Follow-up period.

Condition or disease Intervention/treatment Phase
Anemia Drug: GSK1278863 Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 16-week, Phase 2a, Single-arm, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of GSK1278863 After Switching From Recombinant Human Erythropoietin (rhEPO), in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Chronically Hyporesponsive to rhEPO
Study Start Date : June 1, 2014
Actual Primary Completion Date : March 1, 2016
Actual Study Completion Date : March 16, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: GSK1278863 Arm
Subjects will receive a fixed starting dose of 12 milligrams (mg) GSK1278863 once daily (QD) orally for first 4 weeks. From Week 4 the dose of GSK1278863 will be adjusted based on Hgb levels and evaluated every 4 weeks until Week 16. This starting dose may be changed during the study if there is an early indication of either lack of efficacy or the rate of rise in Hgb is too rapid
Drug: GSK1278863
Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863

Drug: Placebo
Matching placebo tablet for GSK1278863




Primary Outcome Measures :
  1. Percentage of Participants Demonstrating an Increase in Hgb of >=1 g/dL (if Baseline Hgb is <9.5 g/dL), or >=0.5 g/dL (if Baseline Hgb is 9.5-<10 g/dL), or Stay Within Target Range and do Not Drop by >0.5 g/dL (if Baseline Hgb is >= 10 g/dL) at Week 16 [ Time Frame: Week 16 ]
    Percentage of participants with increased Hgb >=1 g/dL (if baseline Hgb is <9.5 g/dL), or >=0.5 g/dL (if baseline Hgb is 9.5-<10 g/dL), or within the target range and not dropped by >0.5 g/dL (if baseline Hgb is >= 10 g/dL) at Week 16 are presented. Participants who were available at the indicated time point were analyzed


Secondary Outcome Measures :
  1. Change From Baseline in Hgb Levels at Week 16 [ Time Frame: Week 16 ]
    Hgb values measured at Week 16 are presented. Change from baseline was calculated as Week 16 minus baseline value . Participants who were available at the indicated time point were analyzed.

  2. Percentage of Time (Days) Hgb Levels Within, Below and Above Target Range at the Indicated Time Point [ Time Frame: Week 12 to Week 16 ]
    The percentage of time in Hgb levels were in target range (10.0 to 11.5 g/dL) between Weeks 12 and 16 for a participant was calculated by adding the total number of days that Hgb is within target range while on treatment during Weeks 12 to 16 and dividing by the total number of days the participant remained on treatment during Weeks 12 to 16 (using Rosendaal linear interpolation method). Similarly, percentage of time above Hgb target range and percentage of time below Hgb target range were calculated. Participants who were available at the indicated time point were analyzed.

  3. Number of Participants Achieving at Least 1 g/dL Increase in Hgb From Baseline at Week 16 [ Time Frame: Baseline and Week 16 ]
    Number of participants achieving at least 1 g/dL increase in Hgb from baseline at Week 16 were presented. Participants who were available at the indicated time point were analyzed.

  4. Number of Participants With Hgb in the Target Range at Week 16 [ Time Frame: Week 16 ]
    The number of participants with Hgb in the target range of 10.0 to 11.5 g/dL at Week 16 were analyzed. Participants who were available at the indicated time point were analyzed.

  5. Number of Participants Reaching Pre-defined Hgb Stopping Criteria [ Time Frame: Up to Week 16 ]
    The number of participants who reached the Hgb stopping criteria of Hgb concentration <7.5 g/dL from baseline to Week 16 were presented. Participants who were available at the indicated time point were analyzed.

  6. Percent Change From Baseline in Hepcidin at Week 16 [ Time Frame: Baseline (Day 1) and Week 16 ]
    Hepcidin is a regulator of iron metabolism. Baseline value for hepcidin is the pre-dose value on Day 1. Percent change was calculated as 100 multiplied by [exponential (log Week 16 value - log Baseline value) minus 1]. Participants who were available at the indicated time point were analyzed.

  7. Change From Baseline in Ferritin at Week 16 [ Time Frame: Baseline (Day 1) and Week 16 ]
    Baseline value for ferritin is the last pre-dose value on Day 1. Change from Baseline in ferritin was calculated as the Week 16 value minus the Baseline value. Participants who were available at the indicated time point were analyzed.

  8. Change From Baseline in Transferrin at Week 16 [ Time Frame: Baseline (Day 1) and Week 16 ]
    Baseline value for transferrin is the last pre-dose value on Day 1. Change from Baseline in transferrin was calculated as the Week 16 value minus the Baseline value. Participants who were available at the indicated time point were analyzed.

  9. Percent Change From Baseline in Transferrin Saturation at Week 16 [ Time Frame: Baseline (Day 1) and Week 16 ]
    Transferrin saturation is measured in percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change is 100 times [exponential (log Week 16 value minus log Baseline value) -1]. Participants who were available at the indicated time point were analyzed.

  10. Change From Baseline in Total Iron at Week 16 [ Time Frame: Baseline (Day 1) and Week 16 ]
    Baseline value for total iron is the last pre-dose value on Day 1. Change from Baseline in total iron was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.

  11. Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 16 [ Time Frame: Baseline (Day 1) and Week 16 ]
    Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline value for total iron binding capacity is the last pre-dose value on Day 1. Change from Baseline in total iron binding capacity was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.

  12. Reticulocyte Hgb Content (CHr) at Week 16 [ Time Frame: Week 16 ]
    Data has been presented for only those participants who were available at indicated timepoints

  13. Mean Corpuscular Volume (MCV) at Week 16 [ Time Frame: Week 16 ]
    Data has been presented for only those participants who were available at indicated time points.

  14. Mean Corpuscular Hemoglobin (MCH) at Week 16 [ Time Frame: Week 16 ]
    Data has been presented for only those participants who were available at indicated time points.

  15. Change From Baseline in Hematocrit at Week 16 [ Time Frame: Baseline (Day 1) and Week 16 ]
    Hematocrit is the ratio of the volume of red blood cells to the total volume of blood. Baseline value for hematocrit is the pre-dose value on Day 1. Change from Baseline in hematocrit was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.

  16. Change From Baseline in Red Blood Cell (RBC) at Week 16 [ Time Frame: Baseline (Day 1) and Week 16 ]
    Baseline value for RBC (or erythrocytes) is the last pre-dose value on Day 1. Change from Baseline in red blood cells was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points

  17. Change From Baseline in Reticulocyte Number at Week 16 [ Time Frame: Baseline (Day 1) and Week 16 ]
    Baseline value for reticulocyte number is the pre-dose value on Day 1. Change from Baseline in reticulocyte number was calculated as the Week 16 value minus the Baseline value. Data has been presented for only those participants who were available at indicated time points.

  18. Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF) [ Time Frame: Baseline (Day 1) to Week 16 ]
    Blood samples were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose, then 1, 2 and 3 hours after first sample), Week 8 (pre-dose), Week 12 (pre-dose and 3 hour post-dose) and Week 16 (pre-dose) for VEGF measurement. The maximum observed percent change from Baseline in VEGF in the subjects was reported. Baseline value for VEGF is the last pre-dose value on Day 1. Percent change was calculated as 100 multiplied by exponential (log observed maximum value minus log Baseline value) minus 1. Participants who were available at the indicated time point were analyzed.

  19. Maximum Observed Change From Baseline in Erythropoietin (EPO) [ Time Frame: Baseline (Day 1) to Week 16 ]
    Blood samples were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose, then 1, 2 and 3 hours after first sample), Week 8 (pre-dose), Week 12 (pre-dose and 3 hour post-dose) and Week 16 (pre-dose) for EPO measurement. The maximum observed change from baseline in EPO was reported. Baseline value for EPO is the last pre-dose value on Day 1. Change from baseline is calculated as the maximum observed value minus the baseline value. Participants who were available at the indicated time point were analyzed.

  20. Final Dose of GSK1278863 [ Time Frame: Up to 16 Weeks ]
    For the first 4 weeks, subjects received 12mg QD of GSK1278863 with dose decrease permitted at Week 2. After 4 weeks of treatment with GSK1278863, need for dose adjustment was evaluated at visits 4, 8 and 12, to maintain hemoglobin within the target range. Target range was defined as: Hgb Criteria of 10.0 to 11.5 g/dL. Data has been presented for only those participants who were available at indicated time points.

  21. Plasma Concentrations of GSK1278863 and Its Metabolites at the Indicated Time Points [ Time Frame: Day 1, Week 4 and Week 12 ]
    Blood samples were collected for individual plasma GSK1278863and metabolite (GSK2391220, GSK2499166, GSK2531403, GSK2531400, GSK2531399, and GSK2531398) concentrations measurement on Day (D) 1 (pre-dose [PrD]), at Week (W) 4 (6-12, 7-13, 8-14, and 9-15 hour [hr] post-dose [PoD), and at W12 (PrD, 1, 2, and 3 hour PoD). Pharmacokinetic population: All participants from whom a PK sample has been obtained and analyzed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hemodialysis (HD) frequency: Stable HD regimen of three to four times weekly for a minimum of 12 weeks. Note: The type and frequency of dialysis must be stable during the study. Isolated ultrafiltration sessions for the purposes of fluid removal are permitted.
  • Dialysis Adequacy: Single-pool dialyzer clearance multiplied by dialyzer time divided by volume of distribution of urea (Kt/Vurea) of >=1.2 based on a historical value obtained within the prior month.
  • rhEPO hyporesponsiveness: Historical and current intravenous (IV) rhEPO and Hgb values. Average epoetin alfa dose and Hgb level for three 4-week periods for a total of 12 weeks prior to Week -4, and during the 4 week run-in period, must be within the following ranges: average epoetin alfa dose >4000 and <=6000 units per session and Hgb >=8.0 and <=9.5 g/dL; average epoetin alfa dose >6000 and <=8000 units per session and Hgb >=8.0 and <=10.0 g/dL; average epoetin alfa dose >8000 and <=10000 units per session and Hgb >=8.0 and <=10.5 g/dL; and average epoetin alfa dose >10000 units per session and Hgb >=8.0 and <=11.0 g/dL.
  • Absolute difference between the Hgb value at Week -4 and Week 0 (Day 1), must be <1.3 g/dL. Note: Subjects who do not meet the criteria after being rescreened twice, should not be entered into the GSK1278863 treatment period and should be withdrawn from the study.
  • Age: >=18 years of age.
  • Q-T Interval Corrected for Heart Rate (QTc): Bazett's Correction of QT Interval (QTcB) <470 msec or QTcB <480 milliseconds (msec) in subjects with bundle branch block. There is no corrected QT interval (QTc) inclusion criterion for a subject with a predominantly paced rhythm.
  • Gender: Female and male subjects. Females: If of childbearing potential, must agree to use one of the approved contraception methods from Screening until completion of the Follow-up Visit OR, of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy or oophorectomy; or postmenopausal defined as 12 months of spontaneous amenorrea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 23.0-116.3 milliinternational units (MIU)/milliliter (mL) (23.0-116.3 international units (IU)/liter (L)) and estradiol <=10 picograms (pg)/mL (<=37 picomole (pmol)/L) is confirmatory]. Females on hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use one of the approved contraception methods if they wish to continue their HRT during the study. Otherwise they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.

Exclusion Criteria:

  • Dialysis modality: Planned change in dialysis modality within the study time period.
  • rhEPO: Use of methoxy polyethylene glycol epoetin beta or darbepoetin within the prior 8 weeks prior to Week -4.
  • Renal transplant: Scheduled renal transplant.
  • Transferrin saturation (TSAT): <20% on the most recent sample taken over the last 12 weeks.
  • Ferritin: <100 nanograms (ng)/mL (<100 micrograms/L) on the most recent sample taken over the last 12 weeks.
  • Vitamin B12: At or below the lower limit of the reference range (may rescreen in a minimum of 8 weeks).
  • Folate: <2.0 ng/mL (<4.5 nanomoles (nmol)/L) (may rescreen in a minimum of 4 weeks).
  • Myocardial infarction or acute coronary syndrome: Within the 8 weeks prior to Week -4.
  • Stroke or transient ischemic attacks (TIAs): Within the 8 weeks prior to Week -4.
  • Heart failure: Class III/IV heart failure, as defined by the New York Heart Association (NYHA) functional classification system diagnosed prior to Week -4.
  • Hypertension: Defined using pre-dialysis vitals (Week -4) of diastolic blood pressure >100 millimeters of mercury (mmHg) or systolic blood pressure >170 mmHg.
  • Thrombotic disease: History of thrombotic disease (e.g., venous thrombosis such as deep vein thrombosis or pulmonary embolism, or arterial thrombosis such as new onset or worsening limb ischemia requiring intervention) within the 8 weeks prior to Week -4, except vascular access thrombosis.
  • Inflammatory disease: Active chronic inflammatory disease that could impact erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis, celiac disease) diagnosed prior to Week -4.
  • Hematological disease: Any hematological disease including those affecting platelets, white or red blood cells (e.g., antibody-mediated pure red cell aplasia, sickle cell anemia, myelodysplastic syndromes, hematological malignancy, myeloma, hemolytic anemia), coagulation disorders (e.g., antiphospholipid syndrome, Protein C or S deficiency), or any other cause of anemia other than renal disease diagnosed prior to Week -4.
  • Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) or evidence at Screening of abnormal liver function tests [alanine transaminase (ALT) or aspartate transaminase (AST) > 2.0 x upper limit of normal (ULN) or total bilirubin > 1.5 x ULN]; or other hepatic abnormalities that in the opinion of the investigator would preclude the subject from participation in the study. NOTE: Those with Hepatitis B or Hepatitis C are eligible provided these exclusions are not met.
  • Major surgery: (excluding vascular access surgery) within the 8 weeks prior to Week -4, or planned during the study.
  • Transfusion: Blood transfusion within the 8 weeks prior to Week -4, or an anticipated need for blood transfusion during the study.
  • Gastrointestinal (GI) Bleeding: Evidence of actively bleeding peptic, duodenal, or esophageal ulcer disease or clinically significant GI bleeding within the 8 weeks prior to Week -4.
  • Ophthalmology disease: History of proliferative retinopathy requiring treatment within the prior 12 months or macular edema requiring treatment.
  • Acute infection: Clinical evidence of acute infection, evidence of underlying infection or history of infection requiring IV antibiotic therapy within the 8 weeks prior to Week -4, and also through to Day 1. Note: IV antibiotics as prophylaxis are allowed.
  • Malignancy: Subjects with a history of malignancy within the prior 5 years, who are receiving treatment for cancer, or who have a strong family history of cancer (e.g., familial cancer disorders), with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated prior to Week -4.
  • Severe allergic reactions: History of severe allergic or anaphylactic reactions or hypersensitivity to excipients in the investigational product.
  • Drugs and supplements: Use of any prescription or non-prescription drugs or dietary supplements that are prohibited from Week -4 until the Follow-up Visit.
  • Prior investigational product exposure: The subject has participated in a clinical trial and has received an experimental investigational product within the prior 30 days to Week -4.
  • Life Expectancy: Life expectancy is considered by the investigator to be less than 6 months.
  • Other conditions: Any other conditions, clinical or laboratory abnormality, or examination finding that the Investigator considers would put the subject at unacceptable risk, or an unwillingness or inability to follow the procedures, or lifestyle and/or dietary restrictions outlined in the protocol.
  • Pregnancy and lactation: Pregnant females as determined by positive serum human chorionic gonadotrophin (hCG) test or women who are lactating at Week -4 or during the trial.
  • Laboratory eligibility criteria will be assessed according to the central laboratory result for the screening samples
  • Subjects who fail screening may be rescreened as soon as the investigator feels they may have subsequently become eligible. However, an individual subject may not be rescreened more than twice. There is no predetermined amount of time required to wait to rescreen a previously ineligible subject. Exceptions are those failing on Hgb or folate who may rescreen in 4 weeks and those failing for Vitamin B12 where rescreening may occur in 8 weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02075463


Locations
United States, California
GSK Investigational Site
Azusa, California, United States, 91702
GSK Investigational Site
Glendale, California, United States, 91204
GSK Investigational Site
Los Angeles, California, United States, 90022
GSK Investigational Site
Los Angeles, California, United States, 90025
GSK Investigational Site
Paramount, California, United States, 90723
GSK Investigational Site
San Diego, California, United States, 92115
GSK Investigational Site
Simi Valley, California, United States, 93065
United States, Connecticut
GSK Investigational Site
Middlebury, Connecticut, United States, 06762
United States, Florida
GSK Investigational Site
Hollywood, Florida, United States, 33024
GSK Investigational Site
Tampa, Florida, United States, 33609
United States, Georgia
GSK Investigational Site
Macon, Georgia, United States, 31217
United States, Michigan
GSK Investigational Site
Southgate, Michigan, United States, 48195
United States, Missouri
GSK Investigational Site
Saint Ann, Missouri, United States, 63074
GSK Investigational Site
Saint Louis, Missouri, United States, 63110
United States, New York
GSK Investigational Site
Amherst, New York, United States, 14226
United States, North Carolina
GSK Investigational Site
Asheville, North Carolina, United States, 28801
United States, Pennsylvania
GSK Investigational Site
Bethlehem, Pennsylvania, United States, 18017
United States, Tennessee
GSK Investigational Site
Knoxville, Tennessee, United States, 37923
United States, Texas
GSK Investigational Site
Houston, Texas, United States, 77004
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT02075463     History of Changes
Other Study ID Numbers: 114837
First Posted: March 3, 2014    Key Record Dates
Results First Posted: June 21, 2017
Last Update Posted: June 21, 2017
Last Verified: April 2017

Keywords provided by GlaxoSmithKline:
recombinant human erythropoietin
GSK1278863
hemodialysis
anemia
Hemoglobin
chronic rhEPO hyporesponsiveness
chronic kidney disease
erythropoiesis stimulating agents
pharmacokinetics

Additional relevant MeSH terms:
Anemia
Kidney Diseases
Renal Insufficiency, Chronic
Hematologic Diseases
Urologic Diseases
Renal Insufficiency
Epoetin Alfa
Glycine
Hematinics
Glycine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs